Skip to search formSkip to main contentSkip to account menu

Clexane

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The aim of this study is to evaluate the efficiency of low‐dose, low‐molecular‐weight heparin (enoxaparin) in the treatment of… 
2001
2001
BACKGROUND The aim of this prospective study was to analyse the group of patients with DVT (deep vein thrombosis) treated at home… 
2001
2001
The anticoagulants, unfractionated heparin and low‐molecular‐weight heparin, demonstrated anti‐inflammatory effects in animal… 
1996
1996
Summary We have previously reported (Brieger D, Dawes J. Thromb Haemost 1994; 72: 275-80) that the prolonged anti-Xa amidolytic… 
1995
1995
Summary Glycosaminoglycans (GAGs) are an important component of endothelial barrier function. Early passage human umbilical vein… 
1994
1994
Low-dose low molecular heparin inhibits T lymphocyte-mediated autoimmune disease and allograft reactions in mice in vivo and in… 
1994
1994
Summary It is widely reported that persistent anti-Xa activity follows administration of low molecular weight heparins. To… 
Review
1990
Review
1990
The pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin were compared by crossover study in healthy volunteers… 
1990
1990
Different low molecular weight heparins have been compared with unfractionated heparin for the prevention of venous thrombosis in…